News
ALDX
9.93
+4.53%
0.43
BRIEF-Aldeyra Therapeutics Announces Completion of Enrollment in Mid-Stage Trial of Chronic Cough Drug
Reuters · 2d ago
Correction: Aldeyra Therapeutics Says Patient Enrollment Complete in Phase 2 Trial for Chronic Cough Treatment Candidate
Correction: Aldeyra Therapeutics Says Patient Enrollment Complete in Phase 2 Trial for Chronic Cough Treatment Candidate
MT Newswires · 2d ago
Aldeyra Therapeutics Enrolls Drug in Phase 2 Trial for Chronic Cough Treatment
Aldeyra Therapeutics Enrolls Drug in Phase 2 Trial for Chronic Cough Treatment
MT Newswires · 2d ago
BioNTech, Coinbase Global, Pharming Group And Other Big Stocks Moving Lower On Monday
Benzinga · 5d ago
UBS, Credit Suisse And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Benzinga · 03/24 10:40
KB Home, Accenture, Netflix And Other Big Stocks Moving Higher On Thursday
Benzinga · 03/23 14:39
Aldeyra Therapeutics Completes Enrollment in Trial for Rare Eye Disease Investigational Drug
Aldeyra Therapeutics Completes Enrollment in Trial for Rare Eye Disease Investigational Drug
MT Newswires · 03/16 09:51
BRIEF-Aldeyra Therapeutics Inc Does Not Have Exposure To Silicon Valley Bank
Reuters · 03/10 21:59
Aldeyra Therapeutics (ALDX) Gets a Buy from SVB Securities
TipRanks · 03/10 21:15
Analysts Are Bullish on Top Healthcare Stocks: Cytokinetics (CYTK), Aldeyra Therapeutics (ALDX)
TipRanks · 03/10 13:10
H.C. Wainwright Reaffirms Their Buy Rating on Aldeyra Therapeutics (ALDX)
TipRanks · 03/10 11:15
Earnings Scheduled For March 9, 2023
Benzinga · 03/09 13:00
BRIEF-Aldeyra Therapeutics Reports Full-Year 2022 Financial Results
Reuters · 03/09 12:35
Aldeyra Therapeutics FY EPS $(1.06) Beats $(1.16) Estimate; Cash, Cash equivalents & Marketable Securities Of $174.3M are Sufficient To Fund Operating Expenses Into 2H of 2024
Benzinga · 03/09 12:05
Aldeyra Therapeutics GAAP EPS of -$1.06 beats by $0.10
Seeking Alpha · 03/09 12:03
Aldeyra Therapeutics Fiscal 2022 Loss Narrows
Aldeyra Therapeutics Fiscal 2022 Loss Narrows
MT Newswires · 03/09 07:49
Earnings Outlook For Aldeyra Therapeutics
Benzinga · 03/08 18:02
Notable earnings before Thursday's open
Seeking Alpha · 03/08 15:27
Aldeyra Therapeutics (ALDX) Investor Presentation - Slideshow
Seeking Alpha · 03/02 18:14
FDA accepts for priority review Aldeyra's ADX-2191 application in retinal cancer
Seeking Alpha · 03/02 12:27
More
Webull provides a variety of real-time ALDX stock news. You can receive the latest news about Aldeyra Therapeu through multiple platforms. This information may help you make smarter investment decisions.
About ALDX
Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in discovering therapies designed to treat immune-mediated diseases. The Company's product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the treatment of systemic and retinal immune-mediated diseases. Its pre-commercial product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the treatment of primary vitreoretinal lymphoma, proliferative vitreoretinopathy, and other rare sight-threatening retinal diseases. Its ADX-629, is an orally administered RASP modulator in clinical development for atopic dermatitis, idiopathic nephrotic syndrome, moderate alcohol-associated hepatitis, chronic cough, and Sjogren-Larsson Syndrome. Its ADX-246 and ADX-248, for geographic atrophy and systemic inflammatory diseases.